Health
Pfizer and BioNTech start early study of combination vaccine to protect against COVID-19 and influenza
Biopharmeceutical firm Pfizer Inc. is teaming up with the German BioNTech SE to conduct an early-stage examine to investigate a vaccination able to defending people in opposition to COVID-19 and influenza.
The businesses introduced on Thursday that the single-dose vaccine candidate can be made up of the Omicron booster shot and the mRNA flu shot produced by Pfizer.
The examine will consider whether or not the shot is tolerable, in addition to safer, for human sufferers or if it has the flexibility to supply a response by the immune system. 100-eighty human members from the U.S. between the ages of 18 and 64 will likely be used within the examine,
“The flexibleness and manufacturing velocity of the mRNA expertise has demonstrated that it’s well-suited for different respiratory illnesses,” mentioned Pfizer’s chief scientific officer Annaliesa Anderson in an announcement. “Pfizer is deeply pleased with our continued work to discover its potential to guard in opposition to influenza and COVID-19 in a single mixture vaccine, which we expect might simplify immunization practices in opposition to these two respiratory pathogens, doubtlessly main to higher vaccine uptake for each illnesses.”
COVID-19 SYMPTOMS REBOUND AFTER PAXLOVID MAY BE DUE TO IMMUNE SYSTEM RESPONSE
Pfizer is working with BioNTech to develop a mix vaccine able to defending in opposition to influenza and COVID-19.
(AP Picture/Steven Senne)
“Even with present seasonal influenza vaccines, the burden of this virus is extreme internationally inflicting 1000’s of deaths and hospitalizations yearly. That is an thrilling step in our ongoing journey with BioNTech as we collectively look to rework the prevention of infectious illnesses world wide,” Anderson added.
The primary participant to obtain the dose was given the mixed vaccine earlier this week. In the meantime, competitor drugmaker Moderna Inc. is working with Novavax to additionally create a vaccine able to combating each COVID-19 and influenza.
Though the U.S. COVID-19 price is declining, corporations are nonetheless seeking to develop totally different protections in opposition to variants of the infectious illness.